Gene therapy developer Tocagen, a San Diego-based biotech, is preparing an initial public stock offering to finance clinical trials of its experimental treatment for high-grade glioma brain cancer.  Tocagen filed the paperwork last week for an IPO that could raise up to $86 million. No gene therapies have yet been approved in the U.S. (Xconomy)